Zag Bio is a startup based in the United States. Brouky records 1 investor associated with the company.
Zag Bio develops thymus-targeted therapies using bifunctional antibodies to induce T cell central tolerance for the treatment of autoimmune diseases.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.